Safinamide..Merck Serono Announces 18-Month Safety and Efficacy Data Phase III Trial

[Stitcher]

Merck Serono Announces 18-Month Safety and Efficacy Data of Phase III Trial of Safinamide. Additional trials expected to be initiated (8/ 22/07)

See Focus on Therapies (http://www.pdpipeline.org)